MUKILTEO, Wash., Dec. 18, 2008 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX) today announced that expanded study results on the company’s HerScan(tm) array comparative genomic hybridization (array CGH) test demonstrated 97% concordance with fluorescent in situ hybridization (FISH) enumeration of the Her2 gene locus. The evaluation was based on 100 additional breast cancer cases and was presented this past week at the 31st Annual San Antonio Breast Cancer Symposium.
